Back to results
US 12,605,473 B2Granted
Methods for making radiolabeled anti-MET binding proteins
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsMarcus Kelly, Dangshe Ma, William Olson
Life of this patent
Estimating the term…
Abstract
Radiolabeled anti-MET antibodies and MET×MET bispecific antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of MET proteins in a subject or sample and methods of monitoring efficacy of treatment of a Met expressing tumor.
Claims28
A method for making a radiolabeled anti-MET binding protein, the method comprising:
- reacting an anti-MET binding protein with a chelating agent having a reactive moiety for conjugation to the anti-MET binding protein to generate a conjugate of anti-MET binding protein-chelating agent, and
- loading a radioactive positron emitter onto the conjugate, whereby the radioactive positron emitter and the chelating agent form a stable complex,
- thereby making the radiolabeled anti-MET binding protein;
- wherein the anti-MET-binding protein comprises (i) three heavy chain complementarity determining regions (HCDRs) in a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NO:
- 2, 10, 18, 26, 34, 42, 50, 58, 66, 74, 82, 90, 98, 106, 114, 122, and 130;
- and (ii) three light chain complementarity determining regions (LCDRs) in a light chain variable region (LCVR) having an amino acid sequence of SEQ ID NO:
- 138.
4 more elements
A method for making a radiolabeled anti-MET binding protein, the method comprising:
- loading a radioactive positron emitter onto a conjugate of an anti-MET binding protein-chelating agent, whereby the radioactive positron emitter and the chelating agent form a stable complex, thereby making the radiolabeled anti-MET binding protein;
- wherein the anti-MET-binding protein comprises (i) three heavy chain complementarity determining regions (HCDRs) in a heavy chain variable region (HCVR) having an amino acid sequence selected from the group consisting of SEQ ID NO:
- 2, 10, 18, 26, 34, 42, 50, 58, 66, 74, 82, 90, 98, 106, 114, 122, and 130;
- and (ii) three light chain complementarity determining regions (LCDRs) in a light chain variable region (LCVR) having an amino acid sequence of SEQ ID NO:
- 138.
2 more elements
Dependencies are inferred from the claim text.